|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Immunomedics
gptkb:Kite_Pharma
gptkb:Pharmacyclics
Acquired Kite Pharma
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:ceo
|
gptkb:Daniel_O'_Day
|
|
gptkbp:clinical_trial
|
multiple ongoing trials
invests heavily in clinical research
COVID-19 treatments
|
|
gptkbp:collaboration
|
various academic institutions
|
|
gptkbp:employees
|
Over 10,000
over 13,000
over 12,000
|
|
gptkbp:focus
|
Antiviral drugs
antiviral drugs
hepatitis C treatment
influenza treatment
HIV/ AIDS treatment
|
|
gptkbp:founded
|
gptkb:1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:global_presence
|
operates in over 35 countries
|
|
gptkbp:headcount
|
approximately 13,000 employees
|
|
gptkbp:headquarters
|
gptkb:Foster_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:innovation
|
focuses on innovative therapies
|
|
gptkbp:instruction_set
|
strong product pipeline
|
|
gptkbp:investment
|
invests in R& D
|
|
gptkbp:market_cap
|
approximately $90 billion (2021)
|
|
gptkbp:net_income
|
$6.66 billion (2020)
|
|
gptkbp:partnership
|
gptkb:Galapagos_NV
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Janssen_Pharmaceuticals
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Eli_Lilly_and_Company
gptkb:Abb_Vie
gptkb:Novartis
Partnership with various research institutions
|
|
gptkbp:partnerships
|
collaborates with various biotech firms
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Foundation
|
|
gptkbp:product
|
gptkb:Yescarta
gptkb:Veklury
gptkb:Zydelig
gptkb:Atripla
gptkb:Sovaldi
gptkb:Truvada
gptkb:Biktarvy
gptkb:Descovy
gptkb:Remdesivir
gptkb:Epclusa
gptkb:Harvoni
Vemlidy
|
|
gptkbp:products
|
antiviral drugs
HIV medications
|
|
gptkbp:related_products
|
gptkb:Atripla
gptkb:Sovaldi
gptkb:Truvada
gptkb:Biktarvy
gptkb:Remdesivir
gptkb:Harvoni
|
|
gptkbp:research_focus
|
gptkb:virus
gptkb:HIV/_AIDS
oncology
autoimmune diseases
inflammation
cardiovascular diseases
respiratory diseases
|
|
gptkbp:revenue
|
$24.4 billion (2020)
$24.69 billion (2020)
|
|
gptkbp:service_area
|
Global
|
|
gptkbp:stock_symbol
|
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Immunomedics
gptkb:Kite_Pharma
Gilead Sciences Canada, Inc.
Gilead Sciences Ireland UC
Gilead Sciences Singapore Pte. Ltd.
Gilead Sciences Australia Pty Ltd.
Gilead Sciences UK Limited
|
|
gptkbp:sustainability
|
community engagement
environmental initiatives
diversity and inclusion programs
healthcare access initiatives
|
|
gptkbp:technology
|
Innovative drug development
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
gilead.com
|
|
gptkbp:bfsParent
|
gptkb:biotechnology
gptkb:W3_C
|
|
gptkbp:bfsLayer
|
3
|